CEFUROXIME MEDO 750 MG

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

CEFUROXIME AS SODIUM

Disponível em:

A.L. MEDI-MARKET LTD.

Código ATC:

J01DC02

Forma farmacêutica:

POWDER FOR SOLUTION FOR INJ/INF

Composição:

CEFUROXIME AS SODIUM 750 MG/VIAL

Via de administração:

I.M, I.V

Tipo de prescrição:

Required

Fabricado por:

MEDOCHEMIE LTD (FACTORY C), CYPRUS

Área terapêutica:

CEFUROXIME

Indicações terapêuticas:

Cefuroxime Medo is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth)• Community acquired pneumonia• Acute exacerbations of chronic bronchitis• Complicated urinary tract infections, including pyelonephritis• Soft-tissue infections: cellulitis, erysipelas and wound infections• Intra-abdominal infections • Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) • nose infections for example, sinusitis • septic arthritis

Data de autorização:

2021-10-31

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CEFUROXIME MEDO 750 MG powder for Solution
for Injection or Infusion.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Vials contain
750 mg
cefuroxime (as cefuroxime sodium).
The total quantity of sodium per vial is 40.65 mg (1.77 mmol).
3.
PHARMACEUTICAL FORM
Powder for solution for injection or infusion.
White or almost white to yellowish powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cefuroxime Medo 750 mg is indicated for the treatment of the
infections listed below in
adults and children, including neonates (from birth) (see sections 4.4
and 5.1).

Community acquired pneumonia

Acute exacerbations of chronic bronchitis

Complicated urinary tract infections, including pyelonephritis

Soft-tissue infections: cellulitis, erysipelas and wound infections

Intra-abdominal infections (see section 4.4)

Prophylaxis against infection in gastrointestinal (including
oesophageal), orthopaedic,
cardiovascular, and gynaecological surgery (including caesarean
section)

Nose infections for example, sinusitis

Septic arthritis
In the treatment and prevention of infections in which it is very
likely that anaerobic
organisms will be encountered, cefuroxime should be administered with
additional
appropriate antibacterial agents.
Consideration should be given to official guidance on the appropriate
use of antibacterial
agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Table 1. Adults and children _

_40 kg _
_ _
INDICATION
DOSAGE
Community acquired pneumonia and acute
exacerbations of chronic bronchitis
_ _
_ _
750 mg every 8 hours
(intravenously or intramuscularly)
Soft-tissue infections: cellulitis, erysipelas
and wound infections.
Intra-abdominal infections
Sinusitis, septic arthritis
750 mg every 8 hours
(intravenously or intramuscularly). For more
severe infections, this dose should be
increased to 1.5g every 8 hours i.v. The
frequency of i.m. or i.v. injections can be
increased to six-hourly if necessary, giving